7 results on '"Finetti, Pascal"'
Search Results
2. PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
- Author
-
Bertucci, Francois, Finetti, Pascal, Monneur, Audrey, Perrot, Delphine, Chevreau, Christine, Le Cesne, Axel, Blay, Jean-Yves, Mir, Olivier, Birnbaum, Daniel, Blay, Jean‐yves, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Claudius Regaud, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Service d'Oncologie Médicale, Centre Léon Bérard [Lyon], Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
0301 basic medicine ,Genome instability ,Male ,Cancer Research ,DNA Repair ,[SDV]Life Sciences [q-bio] ,Poly (ADP-Ribose) Polymerase-1 ,0302 clinical medicine ,PARP1 ,Research Articles ,Aged, 80 and over ,Soft tissue sarcoma ,Sarcoma ,General Medicine ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,PARP1 expression ,Gene Expression Regulation, Neoplastic ,Oncology ,030220 oncology & carcinogenesis ,soft tissue sarcoma ,PARP inhibitor ,Molecular Medicine ,Female ,Research Article ,Adult ,Adolescent ,DNA repair ,DNA damage ,Genomics ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,survival ,lcsh:RC254-282 ,03 medical and health sciences ,Young Adult ,Genetics ,medicine ,Humans ,Gene ,Aged ,Retrospective Studies ,business.industry ,medicine.disease ,Survival Analysis ,030104 developmental biology ,Cancer research ,prognosis ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Soft tissue sarcomas (STSs) are aggressive tumors with few efficient systemic therapies. Poly(ADP-ribose) polymerase-1 (PARP1) inhibitors represent an emerging therapeutic option in tumors with genomic instability. The genomics of STSs is complex in more than half of cases, suggesting a high level of inherent DNA damage and genomic instability. Thus, STSs could be efficiently targeted with PARP inhibitors. Promising preclinical results have been reported, but few data are available regarding PARP1 expression in clinical samples. We examined PARP1 mRNA expression in 1464 clinical samples of STS, including 1432 primary tumors and 32 relapses, and searched for correlations with clinicopathological features, including metastasis-free survival (MFS). Expression was heterogeneous across the samples, not different between primary and secondary tumors, and was correlated to PARP1 DNA copy number. In the 1432 primary tumors, the 'PARP1-high' samples were associated with younger patients, more frequent locations at the extremities, superficial trunk and head and neck, more leiomyosarcomas and other STSs and less liposarcomas and myxofibrosarcomas, more grade 3, more high-risk CINSARC tumors, and more 'chromosomically instable' tumors. They were associated with shorter MFS, independently of other significant prognostic features, including the CINSARC signature. We found a strong involvement of genes overexpressed in the 'PARP1-high' samples in cell cycle, DNA replication, and DNA repair. PARP1 expression refines the prediction of MFS in STSs, and similar expression exists in secondary and primary tumors, supporting the development of PARP1 inhibitors.
- Published
- 2019
3. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease
- Author
-
Jansen, Maurice P.H.M., Sas, Leen, Sieuwerts, Anieta M., Van Cauwenberghe, Caroline, Ramirez-Ardila, Diana, Look, Maxime, Ruigrok-Ritstier, Kirsten, Finetti, Pascal, Bertucci, François, Timmermans, Mieke M., van Deurzen, Carolien H.M., Martens, John W.M., Simon, Iris, Roepman, Paul, Linn, Sabine C., van Dam, Peter, Kok, Marleen, Lardon, Filip, Vermeulen, Peter B., Foekens, John A., Dirix, Luc, Berns, Els M.J.J., and Van Laere, Steven
- Published
- 2015
- Full Text
- View/download PDF
4. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer
- Author
-
Allensworth, Jennifer L., Evans, Myron K., Bertucci, François, Aldrich, Amy J., Festa, Richard A., Finetti, Pascal, Ueno, Naoto T., Safi, Rachid, McDonnell, Donald P., Thiele, Dennis J., Van Laere, Steven, and Devi, Gayathri R.
- Published
- 2015
- Full Text
- View/download PDF
5. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers
- Author
-
Bertucci, François, primary, Rypens, Charlotte, additional, Finetti, Pascal, additional, Guille, Arnaud, additional, Adélaïde, José, additional, Monneur, Audrey, additional, Carbuccia, Nadine, additional, Garnier, Séverine, additional, Dirix, Piet, additional, Gonçalves, Anthony, additional, Vermeulen, Peter, additional, Debeb, Bisrat G., additional, Wang, Xiaoping, additional, Dirix, Luc, additional, Ueno, Naoto T., additional, Viens, Patrice, additional, Cristofanilli, Massimo, additional, Chaffanet, Max, additional, Birnbaum, Daniel, additional, and Van Laere, Steven, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Endometrioid ovarian carcinoma landscape: pathological and molecular characterization.
- Author
-
Nonneville, Alexandre, Kalbacher, Elsa, Cannone, Francesco, Guille, Arnaud, Adelaïde, José, Finetti, Pascal, Cappiello, Maria, Lambaudie, Eric, Ettore, Giuseppe, Charafe, Emmanuelle, Mamessier, Emilie, Provansal, Magali, Bertucci, François, and Sabatier, Renaud
- Subjects
- *
GENE expression , *DNA analysis , *GENE expression profiling , *PROTEIN expression , *CARCINOMA , *UTERINE tumors , *ENDOMETRIUM - Abstract
Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter study involved patients from three European centers. We collected clinical data and formalin‐fixed paraffin‐embedded (FFPE) samples for analysis at the DNA level using panel‐based next‐generation sequencing and array‐comparative genomic hybridization. Additionally, we examined mRNA expression using NanoString nCounter® and protein expression through tissue microarray. We compared EOvC with other ovarian subtypes and uterine endometrioid tumors. Furthermore, we assessed the impact of molecular alterations on patient outcomes, including progression‐free survival (PFS) and overall survival (OS). Preliminary analysis of clinical data from 668 patients, including 86 (12.9%) EOvC, revealed more favorable prognosis for EOvC compared with serous ovarian carcinoma (5‐year OS of 60% versus 45%; P = 0.001) driven by diagnosis at an earlier stage. Immunohistochemistry and copy number alteration (CNA) profiles of 43 cases with clinical data and FFPE samples available indicated that EOvC protein expression and CNA profiles were more similar to endometrioid endometrial tumors than to serous ovarian carcinomas. EOvC exhibited specific alterations, such as lower rates of PTEN loss, mutations in DNA repair genes, and P53 abnormalities. Survival analysis showed that patients with tumors harboring loss of PTEN expression had worse outcomes (median PFS 19.6 months vs. not reached; P = 0.034). Gene expression profile analysis confirmed that EOvC differed from serous tumors. However, comparison to other rare subtypes of ovarian cancer suggested that the EOvC transcriptomic profile was close to that of ovarian clear cell carcinoma. Downregulation of genes involved in the PI3K pathway and DNA methylation was observed in EOvC. In conclusion, EOvC represents a distinct biological entity and should be regarded as such in the development of specific clinical approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Endometrioid ovarian carcinoma landscape: pathological and molecular characterization.
- Author
-
de Nonneville A, Kalbacher E, Cannone F, Guille A, Adelaïde J, Finetti P, Cappiello M, Lambaudie E, Ettore G, Charafe E, Mamessier E, Provansal M, Bertucci F, and Sabatier R
- Abstract
Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter study involved patients from three European centers. We collected clinical data and formalin-fixed paraffin-embedded (FFPE) samples for analysis at the DNA level using panel-based next-generation sequencing and array-comparative genomic hybridization. Additionally, we examined mRNA expression using NanoString nCounter® and protein expression through tissue microarray. We compared EOvC with other ovarian subtypes and uterine endometrioid tumors. Furthermore, we assessed the impact of molecular alterations on patient outcomes, including progression-free survival (PFS) and overall survival (OS). Preliminary analysis of clinical data from 668 patients, including 86 (12.9%) EOvC, revealed more favorable prognosis for EOvC compared with serous ovarian carcinoma (5-year OS of 60% versus 45%; P = 0.001) driven by diagnosis at an earlier stage. Immunohistochemistry and copy number alteration (CNA) profiles of 43 cases with clinical data and FFPE samples available indicated that EOvC protein expression and CNA profiles were more similar to endometrioid endometrial tumors than to serous ovarian carcinomas. EOvC exhibited specific alterations, such as lower rates of PTEN loss, mutations in DNA repair genes, and P53 abnormalities. Survival analysis showed that patients with tumors harboring loss of PTEN expression had worse outcomes (median PFS 19.6 months vs. not reached; P = 0.034). Gene expression profile analysis confirmed that EOvC differed from serous tumors. However, comparison to other rare subtypes of ovarian cancer suggested that the EOvC transcriptomic profile was close to that of ovarian clear cell carcinoma. Downregulation of genes involved in the PI3K pathway and DNA methylation was observed in EOvC. In conclusion, EOvC represents a distinct biological entity and should be regarded as such in the development of specific clinical approaches., (© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.